Linvoseltamab
FDA Rejects Regeneron’s Blood Cancer Bispecific, Delaying Competition with J&J and Pfizer
Regeneron, FDA rejection, blood cancer bispecific, linvoseltamab, multiple myeloma, J&J, Pfizer
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment